Use of Ursodeoxycholic Acid and Cancer Risk for Patients With Primary Biliary Cholangitis

This cohort study uses electronic health record data to compare cancer incidence among adults with primary biliary cholangitis who were or were not treated with ursodeoxycholic acid (UDCA).

Corresponding Author: Xiang Shu, PhD, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 633 Third Ave, New York, NY 10017 (shux@mskcc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.